Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Metabolic Disorder

Treating Krabbe disease with FBX-101 1:58
Treating Krabbe disease with FBX-101
John Maslowski • 27 Jan 2022
LYS-GM101 AAV gene therapy for GM1 gangliosidosis 6:19
LYS-GM101 AAV gene therapy for GM1 gangliosidosis
Michael Hocquemiller • 15 Nov 2021
GNT0003: AAV gene therapy for Crigler-Najjar syndrome 3:42
GNT0003: AAV gene therapy for Crigler-Najjar syndrome
Lorenzo D'Antiga • 18 Nov 2021
The safety of AVR-RD-01 gene therapy for Fabry disease 4:31
The safety of AVR-RD-01 gene therapy for Fabry disease
Mark Thomas • 29 Oct 2021
The unmet medical need for Crigler-Najjar syndrome 2:31
The unmet medical need for Crigler-Najjar syndrome
Lorenzo D'Antiga • 18 Nov 2021
Educating HCPs and patients on novel therapies for metabolic disorders 3:08
Educating HCPs and patients on novel therapies for metabolic disorders
Mark Thomas • 29 Oct 2021
LYS-SAF302 AAV gene therapy for MPS IIIA 2:38
LYS-SAF302 AAV gene therapy for MPS IIIA
Michael Hocquemiller • 15 Nov 2021
Overcoming immunogenicity of gene therapies 1:16
Overcoming immunogenicity of gene therapies
Timothy Miller • 18 Nov 2021
RESKUE: AAV-based gene therapy for Krabbe disease 0:59
RESKUE: AAV-based gene therapy for Krabbe disease
Timothy Miller • 18 Nov 2021
Treating Krabbe disease with AAV-based gene therapies 2:07
Treating Krabbe disease with AAV-based gene therapies
Timothy Miller • 18 Nov 2021
The role of regenerative medicine in treating diabetes 3:22
The role of regenerative medicine in treating diabetes
Lorenzo Piemonti • 11 Nov 2021
The future of regenerative medicine in transplantation 4:31
The future of regenerative medicine in transplantation
Giuseppe Orlando • 11 Nov 2021
Bio-engineering vascularized islet organs for T1D 4:36
Bio-engineering vascularized islet organs for T1D
Lorenzo Piemonti • 11 Nov 2021
Challenges in β cell replacement therapy 3:34
Challenges in β cell replacement therapy
Lorenzo Piemonti • 11 Nov 2021
Tailored nucleases for primary hyperoxaluria 1:57
Tailored nucleases for primary hyperoxaluria
Devyn Smith • 29 Oct 2021
Advanced cell selection for the manufacture of ProTrans cell therapy 2:34
Advanced cell selection for the manufacture of ProTrans cell therapy
Mathias Svahn • 6 Oct 2021
  • 1
  • 2
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy